- Champignon Brands (CSE:SHRM) has been selected for a continuous disclosure review by the British Columbia Securities Commission
- The review relates to the company’s disclosure obligations since it listed on the Canadian Securities Exchange on February 6, 2020
- The company has had a busy year so far, with multiple acquisitions and the appointment of highly-regarded psychiatrist, Dr Roger McIntyre, as its CEO
- In connection with the review, a cease trade order has been implemented pending the filing of several acquisition announcements
- Champignon Brands’ (SHRM) shares are temporarily suspended from trading and were last valued at C$0.89 each
Champignon Brands (CSE:SHRM) has been selected for a continuous disclosure review by the British Columbia Securities Commission.
Such a review is designed to evaluate any deficiencies made by reporting issuers in the hope that they can be rectified for future announcements.
Champignon Brands listed on the Canadian Securities Exchange on February 6, 2020, and the review by the British Columbia Securities Commission will look at the disclosure surrounding recent acquisitions that have been made by the company since then.
Despite its recent listing, Champignon Brands has had a busy year with a number of significant milestones.
Perhaps most notable was the appointment of Dr Roger McIntyre, who replaced Gareth Birdsall as CEO in mid-May. Roger is a Professor of Psychiatry and Pharmacology at the University of Toronto, and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto.
In addition, the company acquired a 75 per cent stake in the Canadian Rapid Treatment Centre of Excellence in mid-April, a ketamine clinic in Mississauga which offers treatments for a variety of conditions, including depression, bipolar disorder, post-traumatic stress disorder and obsessive-compulsive disorder.
Commenting on the review, Roger said that with the recent growth and interest in the treatment of critical conditions using alternative methods, ensuring the satisfaction of disclosure obligations is of vital importance.
“Ensuring fulsome and timely disclosure is vital to the success of our company, and development of our industry with the investing public.
“We look forward to working with staff of the British Columbia Securities Commission to complete their review, and are hopeful that trading will resume as soon as possible,” he added.
In connection with the review, a cease trade order has been implemented pending the filing of several acquisition announcements. These include the acquisitions of Artisan Growers, Novo Formulations and Tassili Life Sciences.
Champignon Brands’ (SHRM) shares are temporarily suspended from trading and were last valued at C$0.89 each.